Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan; 2 Depart- ment of Clinical, Neuroand Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit, Amsterdam, The Netherlands; 3 Department of Psychiatry & Centre for Urban Mental Health, University of Amsterdam, Amsterdam, The Netherlands; 4 Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK; 5 Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK; 6 Department of Neu- ropsychiatry, University of Tokyo Hospital, Tokyo, Japan; 7 Department of Psychology, Vanderbilt University, Nashville, TN, USA
Список исп. литературыСкрыть список
1. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357-66.
2. Cuijpers P, Quero S, Noma H et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry 2021; 20: 283-93.
3. Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653-61.
4. Sim K, Lau WK, Sim J et al. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol 2015; 19: pyv076.
5. Cuijpers P, Hollon SD, van Straten A et al. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open 2013; 3:e002542.
6. Breedvelt JJF, Brouwer ME, Harrer M et al. Psychological interventions as an alternative and add-on to antidepressant medication to prevent depressive relapse: systematic review and meta-analysis. Br J Psychiatry (in press).
7. Jorm AF, Patten SB, Brugha TS et al. Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry 2017; 16: 90-9.
8. Luo Y, Kataoka Y, Ostinelli EG et al. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey based analysis. Front Psychiatry 2020; 11: 35.
9. Shinohara K, Efthimiou O, Ostinelli EG et al. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis. BMJ Open 2019; 9:e027574.
10. Furukawa TA, Miura T, Chaimani A et al. Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review. BMC Res Notes 2016; 9: 218.
11. Hollon SD. Is cognitive therapy enduring or antidepressant medications iatrogenic? Depression as an evolved adaptation. Am Psychol 2020; 75: 1207-18.
12. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777-84.
13. Cuijpers P, Karyotaki E, Ciharova M. A meta-analytic database of randomised trials on psychotherapies for depression. www.osf.io/825c6.
14. Breedvelt JJF, Warren FC, Brouwer ME et al. Individual participant data (IPD) meta-analysis of psychological relapse prevention interventions versus control for patients in remission from depression: a protocol. BMJ Open 2020; 10:e034158.
15. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(Suppl.):28-34.
16. Campbell LF, Norcross JC, Vasquez MJ et al. Recognition of psychotherapy effectiveness: the APA resolution. Psychotherapy 2013; 50: 98-101.
17. Cuijpers P, Noma H, Karyotaki E et al. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. JAMA Psychiatry 2019; 76: 700-7.
18. Karyotaki E, Efthimiou O, Miguel C et al. Internet-based cognitive behavioral therapy for depression: a systematic review and individual patient data network meta-analysis. JAMA Psychiatry 2021; 78: 361-71.
19. Furukawa TA, Suganuma A, Ostinelli EG et al. Dismantling, optimising and personalising internet cognitive-behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. Lancet Psychiatry 2021; 8: 500-11.
20. Cuijpers P, van Straten A, Andersson G et al. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies.
J Consult Clin Psychol 2008; 76: 909-22.
21. Cuijpers P, Karyotaki E, de Wit L et al. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. Psychother Res 2020; 30: 279-93.
22. Cuijpers P, Noma H, Karyotaki E et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 2020; 19: 92-107.
23. Furukawa TA, Cipriani A, Barbui C et al. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005; 20: 49-52.
24. da Costa BR, Rutjes AW, Johnston BC et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. Int J Epidemiol 2012; 41: 1445-59.
25. Sterne JAC, Savovic J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
26. Bakbergenuly I, Hoaglin DC, Kulinskaya E. Pitfalls of using the risk ratio in meta-analysis. Research Synthesis Methods 2019; 10: 398-419.
27. Doi SA, Furuya-Kanamori L, Xu C et al. Questionable utility of the relative risk in clinical research: a call for change to practice. J Clin Epidemiol (in press).
28. White IR, Turner RM, Karahalios A et al. A comparison of arm-based and contrast-based models for network meta-analysis. Stat Med 2019; 38: 5197-213.
29. Dias S, Welton NJ, Caldwell DM et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29: 932-44.
30. Higgins JP, Jackson D, Barrett JK et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012; 3: 98-110.
31. Turner RM, Davey J, Clarke MJ et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012; 41: 818-27.
32. Peters JL, Sutton AJ, Jones DR et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61: 991-6.
33. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
34. Salanti G, Chaimani A, Furukawa TA et al. Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis. Int J Epidemiol 2018; 47: 1454-64.
35. Papakonstantinou T, Nikolakopoulou A, Higgins JPT et al. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 2020; 16:e1080.
36. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the ‘number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002; 31: 72-6.
37. Alhazzani W, Walter SD, Jaeschke R et al. Does treatment lower risk? Understanding the results. In: G Guyatt, D Rennie, MO Meade et al (eds). Users’ guides to the medical literature: a manual for evidence-based clinical practice, 3rd ed. New York: McGraw-Hill, 2014: 87-93.
38. JP Higgins, J Thomas (eds). Cochrane handbook for systematic reviews of interventions, version 6. https://training.cochrane.org/handbook/current.
39. White IR. Network meta-analysis. Stata J 2015; 15: 951-85.
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
41. Klein DF. Preventing hung juries about therapy studies. J Consult Clin Psychol 1996; 64: 81-7.
42. DeRubeis RJ, Zajecka J, Shelton RC et al. Prevention of recurrence after recovery from a major depressive episode with antidepressant medication alone or in combination with cognitive behavioral therapy: phase 2 of a 2-phase randomized clinical trial. JAMA Psychiatry 2020; 77: 237-45.
43. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. World Psychiatry 2019; 18: 276-85.
44. Guidi J, Fava GA. Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: a systematic review and meta-analysis. JAMA Psychiatry 2021; 78: 261-9.
45. Lavori PW, Dawson R. Dynamic treatment regimes: practical design considerations. Clin Trials 2004; 1: 9-20.
46. Breedvelt JJF, Warren FC, Segal Z et al. Continuation of antidepressants vs sequential psychological interventions to prevent relapse in depression. An individual participant data meta-analysis. JAMA Psychiatry (in press).
47. Hepner KA, Greenwood GL, Azocar F et al. Usual care psychotherapy for depression in a large managed behavioral health organization. Adm Policy Ment Health 2010; 37: 270-8.
48. van Ommeren M. Targets and outcomes of psychological interventions: implications for guidelines and policy. World Psychiatry 2019; 18: 295-6.
49. Jarrett RB. Can we help more? World Psychiatry 2020; 19: 246-7